Neuroinflammation predicts disease progression in progressive supranuclear palsy

摘要: Abstract Objective In addition to tau pathology and neuronal loss, neuroinflammation occurs in progressive supranuclear palsy (PSP). We test the hypotheses that baseline vivo assessments of regional ([11C]PK11195 PET), ([18F]AV-1451 atrophy (structural MRI) predict disease progression. Methods Seventeen patients with PSP-Richardson’s syndrome underwent a multi-modal imaging assessment. Disease severity was measured at serially up 4 years PSP-rating-scale (average interval 5 months). Regional grey-matter volumes PET ligand binding potentials were summarised by three Principal Component Analyses (PCAs). A linear mixed effects model applied longitudinal scores. Single-modality predictors regressed against individuals’ estimated rate progression identify prognostic value markers. Results The PCA factors reflecting burden brainstem cerebellum correlated subsequent annual change PSP-rating-scale. PCA-derived markers brain same regions. However, MRI alone did not clinical Conclusions Molecular can PSP. These data encourage evaluation immunomodulatory approaches disease-modifying therapies PSP, potential for stratify early phase trials.